Trial site
Ulm
Ulm, 89081, GermanyNot linked to an institution yet
- 10running trials
- 16closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 26 trials
- Phase 12 trials
- Phase 42 trials
- Phase 2/31 trial
- Status
- Completed14 trials
- Active, not recruiting6 trials
- Recruiting4 trials
- Terminated2 trials
- Lead sponsor
- Novartis Pharmaceuticals26 trials
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.
NCT05630001· Phase 3· Novartis Pharmaceuticals· Source
Completed
Characterizing Guideline Adoption and Treatment Quality in Clinical Routine of German HFrEF Care
NCT06004453· Novartis Pharmaceuticals· Source
Completed
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
NCT05562934· Phase 2· Novartis Pharmaceuticals· Source
Completed
A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting
NCT05362903· Novartis Pharmaceuticals· Source
Terminated
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
NCT04952753· Phase 2· Novartis Pharmaceuticals· Source
Completed
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
NCT04679935· Phase 4· Novartis Pharmaceuticals· Source
Completed
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
NCT04539041· Phase 1· Novartis Pharmaceuticals· Source
Terminated
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
NCT04266301· Phase 3· Novartis Pharmaceuticals· Source
Completed
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
NCT04023552· Phase 3· Novartis Pharmaceuticals· Source
Completed
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
NCT03798626· Phase 1· Novartis Pharmaceuticals· Source
Completed
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment
NCT06311383· Novartis Pharmaceuticals· Source
Completed
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
NCT03056755· Phase 2· Novartis Pharmaceuticals· Source
Completed
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
NCT01828099· Phase 3· Novartis Pharmaceuticals· Source
Completed
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
NCT01828112· Phase 3· Novartis Pharmaceuticals· Source
Completed
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
NCT01784068· Phase 2· Novartis Pharmaceuticals· Source
Completed
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
NCT01698905· Phase 2· Novartis Pharmaceuticals· Source
Report an error